Bremelanotide

Bremelanotide
Clinical data

ATC code	None
Legal status
Legal status	US: Unscheduled
Pharmacokinetic data
Biological half-life	120 minutes
Identifiers
IUPAC name (3S,6S,9R,12S,15S,23S)-15-[(N-Acetyl-L-norleucyl)amino]-9-benzyl-6-{3-[(diaminomethylidene)amino]propyl}-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxylic acid
CAS Number	189691-06-3^Y
PubChem (CID)	9941379
ChemSpider	8116997^Y
UNII	6Y24O4F92S^Y
KEGG	D06569^N
ChEMBL	CHEMBL2070241^N
Chemical and physical data
Formula	C₅₀H₆₈N₁₄O₁₀
Molar mass	1025.2 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(C)N[C@@H](CCCC)C(N[C@@H]1C(N[C@@H](CC2=CNC=N2)C(N[C@H](CC3=CC=CC=C3)C(N[C@@H](CCC/N=C(N)\N)C(N[C@@H](CC4=CNC5C=CC=CC45)C(N[C@@H](CCCCNC(C1)=O)C(O)=O)=O)=O)=O)=O)=O)=O
InChI InChI=1S/C50H68N14O10/c1-3-4-16-35(58-29(2)65)43(67)64-41-25-42(66)54-20-11-10-18-37(49(73)74)60-46(70)39(23-31-26-56-34-17-9-8-15-33(31)34)62-44(68)36(19-12-21-55-50(51)52)59-45(69)38(22-30-13-6-5-7-14-30)61-47(71)40(63-48(41)72)24-32-27-53-28-57-32/h5-9,13-15,17,26-28,35-41,56H,3-4,10-12,16,18-25H2,1-2H3,(H,53,57)(H,54,66)(H,58,65)(H,59,69)(H,60,70)(H,61,71)(H,62,68)(H,63,72)(H,64,67)(H,73,74)(H4,51,52,55)/t35-,36-,37-,38+,39-,40-,41-/m0/s1^Y Key:FFHBJDQSGDNCIV-MFVUMRCOSA-N^Y
^NY (what is this?)

Bremelanotide (ⁱ/ˌbrɛmᵻˈlænətaɪd/) INN, USAN), formerly known as PT-141, is a peptide drug which has been under development by Palatin Technologies as a treatment for female sexual dysfunction (FSD), hemorrhagic shock, and reperfusion injury. Bremelanotide was originally tested for intranasal administration in treating FSD but this application was temporarily discontinued in 2008 after concerns were raised over increased blood pressure seen with bremelanotide administration in some patients. As of December 2014, Palatin is conducting a human phase III study using a subcutaneous drug delivery system that appears to have little effect on blood pressure.